Breaking News Instant updates and real-time market news.

PANW

Palo Alto Networks

$176.04

-0.46 (-0.26%)

06:31
11/30/18
11/30
06:31
11/30/18
06:31

Palo Alto Networks price target lowered to $249 from $267 at Jefferies

Jefferies analyst John DiFucci lowered his price target for Palo Alto Networks to $249 following the company's "solid" Q1 results. The company's new business growth metrics were mixed, but were up against "extremely difficult comps," DiFucci tells investors in a post-earnings research note. He points out, however, that Palo Alto exceeded fiscal Q1 expectations across most metrics as the company "continues to build out its platform and strengthen its cloud security offering." DiFucci keeps a Buy rating on the shares.

  • 03

    Dec

  • 05

    Dec

  • 06

    Dec

  • 07

    Dec

  • 13

    Dec

  • 19

    Dec

  • 09

    Jan

  • 10

    Jan

PANW Palo Alto Networks
$176.04

-0.46 (-0.26%)

11/30/18
FANA
11/30/18
UPGRADE
Target $240
FANA
Strong Buy
Palo Alto Networks upgraded to Strong Buy from Outperform at First Analysis
First Analysis analyst Howard Smith upgraded Palo Alto Networks to Strong Buy with an unchanged price target of $240. The "strong" fiscal Q1 results and above-consensus fiscal 2019 outlook reinforce the view that "solid global execution and the expansion of its resonating enterprise security platform should reward shareholders," Smith tells investors in a research note. Further, he believes the recent slide in the shares has created a more compelling entry point.
11/27/18
JMPS
11/27/18
NO CHANGE
Target $270
JMPS
Outperform
Palo Alto Networks checks support above consensus view, says JMP Securities
JMP Securities analyst Erik Suppiger said feedback from his channel checks, and the results of the other firewall vendors this quarter, lead him to continue to believe Palo Alto Networks' core firewall business remains robust and that the company will report Q1 results that top consensus estimates. He also expects the company to guide in-line to slightly higher than the Q2 consensus, added Suppiger, who keeps an Outperform rating and $270 price target on Palo Alto shares.
11/19/18
UBSW
11/19/18
NO CHANGE
Target $232
UBSW
Neutral
Palo Alto Networks lack of visibility one reason for weakness, says UBS
UBS analyst Fatima Boolani noted Palo Alto Networks' shares are down roughly 30% from its mid-September highs and she sees several reasons. The pace of leadership transitions has stoked concerns of execution risks and strategy shift, combined with limited visibility into the growth/investment framework, along with lingering concerns of large and/or dilutive M&A, has pushed its valuation down to five-year troughs, said Boolani. She maintained her Neutral rating and $232 price target on Palo Alto shares.
11/15/18
JMPS
11/15/18
NO CHANGE
JMPS
Market Perform
Cisco results bode well for Arista Networks, Nutanix, says JMP Securities
JMP Securities analyst Erik Suppiger noted that Cisco (CSCO) reported Q1 EPS and revenues ahead of consensus, stating that he believes the "robust" results bode well for the broader networing and security markets, including vendors such as Arista Networks (ANET), Nutanix (NTNX), Extreme Networks (EXTR) and Palo Alto Networks (PANW). Service provider bookings had positive growth for the second consecutive quarter, though management acknowledged that the growth may not be sustainable and Suppiger said he thinks this quarter included a large deal with T-Mobile (TMUS). The strength in data center and campus switching that Cisco called out suggests market demand trends are favorable for Arista and Extreme Networks, said the analyst. The strength in Cisco's hyperconverged infrastructure product, HyperFlex, suggests demand is favorable for Nutanix, he added. Suppiger, who views Cisco shares as fairly valued, keeps a Market Perform rating on the stock.

TODAY'S FREE FLY STORIES

MDWD

MediWound

$2.86

-0.04 (-1.38%)

07:11
11/14/19
11/14
07:11
11/14/19
07:11
Hot Stocks
MediWound expects to initiate EscharEx Phase 2 study in Q4 »

Launched the next stage…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 20

    Nov

  • 21

    Nov

MDWD

MediWound

$2.86

-0.04 (-1.38%)

07:10
11/14/19
11/14
07:10
11/14/19
07:10
Hot Stocks
MediWound expects $10M-$12M in cash use in 2019 »

The company said,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 20

    Nov

  • 21

    Nov

CSCO

Cisco

$48.44

0.06 (0.12%)

07:10
11/14/19
11/14
07:10
11/14/19
07:10
Recommendations
Cisco analyst commentary  »

Cisco price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 10

    Dec

  • 12

    Feb

ROLL

RBC Bearings

$165.06

-1.19 (-0.72%)

07:09
11/14/19
11/14
07:09
11/14/19
07:09
Downgrade
RBC Bearings rating change  »

RBC Bearings downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSIQ

Canadian Solar

$14.67

-2.84 (-16.22%)

07:09
11/14/19
11/14
07:09
11/14/19
07:09
Hot Stocks
Canadian Solar announces partnership with Korea Electric Power »

Canadian Solar announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

MDWD

MediWound

$2.86

-0.04 (-1.38%)

07:09
11/14/19
11/14
07:09
11/14/19
07:09
Earnings
MediWound reports Q3 EPS ex-items (1c), consensus (15c) »

Reports Q3 revenue $5.1M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 20

    Nov

  • 21

    Nov

MOTS

Motus GI Holdings

$1.77

-0.09 (-4.84%)

07:09
11/14/19
11/14
07:09
11/14/19
07:09
Earnings
Motus GI Holdings reports Q3 EPS (18c), consensus (25c) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

WMT

Walmart

$121.06

1.93 (1.62%)

07:08
11/14/19
11/14
07:08
11/14/19
07:08
Earnings
Walmart raises FY20 EPS view to 'increase slightly' from FY19 »

Prior guidance was "…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

CORV

Correvio

$2.20

-0.135 (-5.79%)

07:08
11/14/19
11/14
07:08
11/14/19
07:08
Earnings
Correvio reports Q3 EPS (23c), consensus (17c) »

"On the commercial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 24

    Dec

VBLT

VBL Therapeutics

$1.26

0.005 (0.40%)

07:07
11/14/19
11/14
07:07
11/14/19
07:07
Hot Stocks
VBL Therapeutics continues to advance development of MOSPD2 antibodies »

VBL continues to advance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 21

    Nov

BTAI

BioXcel Therapeutics

$4.50

0.06 (1.35%)

07:07
11/14/19
11/14
07:07
11/14/19
07:07
Earnings
BioXcel Therapeutics reports Q3 EPS (57c), consensus (65c) »

"We are pleased with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

VBLT

VBL Therapeutics

$1.26

0.005 (0.40%)

07:06
11/14/19
11/14
07:06
11/14/19
07:06
Hot Stocks
VBL Therapeutics expects to begin NCI-sponsored trial of VB-111 by year-end »

An NCI-sponsored trial of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 21

    Nov

WMT

Walmart

$121.06

1.93 (1.62%)

07:06
11/14/19
11/14
07:06
11/14/19
07:06
Hot Stocks
Walmart reports Q3 U.S. SSS up 3.2% »

Q3 U.S. comp sales…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

MITO

Stealth Biotherapeutics

$7.20

0.35 (5.11%)

07:05
11/14/19
11/14
07:05
11/14/19
07:05
Earnings
Stealth Biotherapeutics reports Q3 EPS (4c), consensus (4c) »

"We're…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

BIIB

Biogen

$281.71

-9.67 (-3.32%)

, ALKS

Alkermes

$19.39

-0.5 (-2.51%)

07:05
11/14/19
11/14
07:05
11/14/19
07:05
Hot Stocks
MS Society asks Biogen, Alkermes to keep Vumerity price raises below inflation »

The National Multiple…

BIIB

Biogen

$281.71

-9.67 (-3.32%)

ALKS

Alkermes

$19.39

-0.5 (-2.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VBLT

VBL Therapeutics

$1.26

0.005 (0.40%)

07:05
11/14/19
11/14
07:05
11/14/19
07:05
Hot Stocks
VBL Therapeutics expects cash to fund requirements for two years »

At September 30, 2019,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 21

    Nov

XCUR

Exicure

$2.45

-0.14 (-5.41%)

, AGN

Allergan

$181.56

-0.38 (-0.21%)

07:05
11/14/19
11/14
07:05
11/14/19
07:05
Hot Stocks
Exicure, Allergan subsidiary enter collaboration to find hair loss treatments »

Exicure (XCUR) announced…

XCUR

Exicure

$2.45

-0.14 (-5.41%)

AGN

Allergan

$181.56

-0.38 (-0.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VBLT

VBL Therapeutics

$1.26

0.005 (0.40%)

07:05
11/14/19
11/14
07:05
11/14/19
07:05
Earnings
VBL Therapeutics reports Q3 EPS (14c), consensus (14c) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 21

    Nov

WMT

Walmart

$121.06

1.93 (1.62%)

07:05
11/14/19
11/14
07:05
11/14/19
07:05
Earnings
Walmart reports Q3 adjusted EPS $1.16, consensus $1.09 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

TJX

TJX

$58.45

0.505 (0.87%)

, ROST

Ross Stores

$111.38

0.41 (0.37%)

07:04
11/14/19
11/14
07:04
11/14/19
07:04
Recommendations
TJX, Ross Stores, Burlington Stores, Nordstrom, Macy's analyst commentary  »

Guggenheim raises price…

TJX

TJX

$58.45

0.505 (0.87%)

ROST

Ross Stores

$111.38

0.41 (0.37%)

BURL

Burlington Stores

$199.23

-1.14 (-0.57%)

JWN

Nordstrom

$37.18

0.28 (0.76%)

M

Macy's

$16.06

-0.02 (-0.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 20

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 26

    Nov

LPTX

Leap Therapeutics

$1.17

-0.035 (-2.92%)

07:04
11/14/19
11/14
07:04
11/14/19
07:04
Earnings
Leap Therapeutics reports Q3 EPS (33c), consensus (33c) »

"The body of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIA

Viacom

$25.14

-0.615 (-2.39%)

, VIAB

Viacom

$22.04

-0.52 (-2.31%)

07:04
11/14/19
11/14
07:04
11/14/19
07:04
Earnings
Viacom reports Q4 adj. EPS 79c, consensus 75c »

Reports Q4 revenue…

VIA

Viacom

$25.14

-0.615 (-2.39%)

VIAB

Viacom

$22.04

-0.52 (-2.31%)

CBS

CBS

$36.84

-0.935 (-2.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 14

    Nov

  • 09

    Dec

FULC

Fulcrum Therapeutics

$8.40

0.405 (5.07%)

07:02
11/14/19
11/14
07:02
11/14/19
07:02
Hot Stocks
Fulcrum Therapeutics expects to file IND for FTX-6058 in mid-2020 »

n October 2019, Fulcrum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

FULC

Fulcrum Therapeutics

$8.40

0.405 (5.07%)

07:02
11/14/19
11/14
07:02
11/14/19
07:02
Hot Stocks
Fulcrum Therapeutics expects cash to fund requirements into 3Q21 »

As of September 30, 2019,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

TRIP

TripAdvisor

$30.83

-0.87 (-2.74%)

, GOOGL

Alphabet Class A

$1,296.00

-1.18 (-0.09%)

07:01
11/14/19
11/14
07:01
11/14/19
07:01
Recommendations
TripAdvisor, Alphabet Class A, Alphabet analyst commentary  »

TripAdvisor price target…

TRIP

TripAdvisor

$30.83

-0.87 (-2.74%)

GOOGL

Alphabet Class A

$1,296.00

-1.18 (-0.09%)

GOOG

Alphabet

$1,298.00

-0.77 (-0.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Nov

  • 26

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.